NGM Biopharmaceuticals Revenue and Competitors

Location

$420.4M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • NGM Biopharmaceuticals's estimated annual revenue is currently $76.7M per year.(i)
  • NGM Biopharmaceuticals received $106.0M in venture funding in March 2015.
  • NGM Biopharmaceuticals's estimated revenue per employee is $435,739
  • NGM Biopharmaceuticals's total funding is $420.4M.
  • NGM Biopharmaceuticals's current valuation is $1.2B. (January 2022)

Employee Data

  • NGM Biopharmaceuticals has 176 Employees.(i)
  • NGM Biopharmaceuticals grew their employee count by -32% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$1.1M70%N/AN/A
#4
$2.3M15150%N/AN/A
#5
$1.4M90%N/AN/A
#6
$11.5M74-12%N/AN/A
#7
$0.4M27510%$236.7MN/A
#8
$4M51-74%$160MN/A
#9
$2.5M1633%N/AN/A
#10
$3.3M21-12%N/AN/A
Add Company

NGM Bio is a research-driven, clinical-stage biopharmaceutical company with a passion to improve the lives of those struggling with serious diseases. Our expertise in drug discovery and translational development, coupled with the significant resources from our partnership with Merck, is driving development of transformational medicines that dramatically improve human health. Our initial R&D focus has been to develop a portfolio of high-impact therapeutics for the underserved patient populations who suffer from cardio-metabolic and liver diseases. We believe that our research expertise comprehensive and grounded in fundamental, interrelated mechanisms of human biology is capable of driving the development of new therapies for a wide range of other disease areas as well, such as cancer. NGM Bio's comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. As we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. Coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. All of NGM Bio's clinical candidates are first-in-class therapies and several are modulating targets or pathways that were first identified by NGM Bio.

keywords:N/A

$420.4M

Total Funding

176

Number of Employees

$76.7M

Revenue (est)

-32%

Employee Growth %

$1.2B

Valuation

N/A

Accelerator

NGM Biopharmaceuticals News

2022-04-20 - How Does NGM Biopharmaceuticals Inc (NGM) Stock Rank on Wall Street Thursday?

That average ranking earns NGM Biopharmaceuticals Inc an Analyst Rating of 72, which is better than 72% of stocks based on data compiled by...

2022-04-19 - Zacks: Brokerages Anticipate NGM Biopharmaceuticals, Inc ...

NGM Biopharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and...

2022-04-17 - NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) used to be a NASH player with some promise. However, in June last year, its NASH drug aldafermin...

2021-08-23 - NGM Biopharmaceuticals : Bio Discloses Fourth Oncology Development Candidate, 831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research

Publication describes NGM’s discovery of ILT3’s functional ligand, fibronectin, a key component of the tumor stroma ILT3-fibronectin interactions within the tumor microenvironment may form a stromal checkpoint that actively suppresses myeloid cell function and inhibits antitumor immunity NGM831 ...

2021-07-22 - NGM Biopharmaceuticals : Announces Completion of Enrollment in Phase 2 CATALINA Study of 621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Geographic atrophy is a progressive, irreversible retinal degenerative disease that can lead to blindness, with no currently approved treatmentsNGM621 is a monoclonal antibody against complement C3, a protein implicated in the pathophysiology of geographic atrophy, and is engineered with the goa ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$23.4M17811%$319.7M
#2
$60.7M1811%N/A
#3
$23.4M18445%N/A
#4
$37.2M192-7%$92.1M
#5
$47.7M19722%N/A

NGM Biopharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2010-03-16$51.0MBArticle
2013-07-19$50.0MCMultipleArticle
2015-03-27$106.0MEArticle